NuProbe Closes $50M in New Fundraising
Houston, TX, June 02, 2022 (GLOBE NEWSWIRE) -- NuProbe Global, a genomics and molecular diagnostics company, announces the close of its $50M fundraising, co-led by AstraZeneca-CICC Fund, CR-CP Life Science Fund, and Panlin Capital. Existing NuProbe investors Sequoia Capital China, Biotrack Capital, and Yonghua Capital and new investors Pappas Capital, Haoreng Capital, and Deguan Capital also participated in the round. CEC Capital served as the financial advisor for this fundraising. The funds will be used to expand commercial operations, accelerate IVD product clinical studies and regulatory submissions, and develop new genomics and molecular diagnostics technologies.
© 2022 Pappas Capital, LLC. ALL RIGHTS RESERVED.